Method Article

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust

3K views

⸱

DOI:

10.3791/64862

⸱

January 6th, 2023

 ,  ,  ,  ,  ,  ,  , 
1Key Laboratory of Industrial Dust Control and Occupational Health of the Ministry of Education, Anhui University of Science and Technology, 2Key Laboratory of Industrial Dust Deep Reduction and Occupational Health and Safety of Anhui Higher Education Institutes, Anhui University of Science and Technology, 3Anhui Province Engineering Laboratory of Occupational Health and Safety, 4School of Medicine, Department of Medical Frontier Experimental Center, Anhui University of Science and Technology

* These authors contributed equally

In This Article

Summary

This protocol describes a method for establishing a mouse model of silicosis through repeated exposure to silica suspensions via a nasal drip. This model can efficiently, conveniently, and flexibly mimic the pathological process of human silicosis with high repeatability and economy.

Abstract

Silicosis can be caused by exposure to respiratory crystalline silica dust (CSD) in an industrial environment. The pathophysiology, screening, and treatment of silicosis in humans have all been extensively studied using the mouse silicosis model. By repeatedly making mice inhale CSD into their lungs, the mice can mimic the clinical symptoms of human silicosis. This methodology is practical and efficient in terms of time and output and does not cause mechanical injury to the upper respiratory tract due to surgery. Furthermore, this model can successfully mimic acute/chronic transformation process of silicosis. The main procedures were as follows. The sterilized 1-5 µm CSD powder was fully ground, suspended in saline, and dispersed in an ultrasonic water bath for 30 min. Mice under isoflurane-induced anesthesia switched from shallow rapid breathing to deep, slow aspiration for approximately 2 s. The mouse was placed in the palm of a hand, and the thumb tip gently touched the lip edge of the mouse's jaw to straighten the airway. After each exhalation, the mice breathed in the silica suspension drop by drop through one nostril, completing the process within 4-8 s. After the mice's breathing had stabilized, their chest was stroked and caressed to prevent the inhaled CSD from being coughed up. The mice were then returned to the cage. In conclusion, this model can quantify CSD along the typical physiological passage of tiny particles into the lung, from the upper respiratory tract to the terminal bronchioles and alveoli. It can also replicate the recurrent exposure of employees due to work. The model can be performed by one person and does not need expensive equipment. It conveniently and effectively simulates the disease features of human silicosis with high repeatability.

Introduction

Workers are inevitably exposed to irregular crystalline silica dust (CSD), which can be inhaled and is more toxic in numerous occupational contexts, including mining, pottery, glass, quartz processing, and concrete1,2. A chronic dust inhalation condition known as silicosis causes progressive lung fibrosis3. According to epidemiological data, the incidence of silicosis has been declining globally over the past few decades, but in recent years, it has been increasing and affecting younger people4,5,6. The underlying mechanism of silicosis presents a significant challenge for scientific research due to its insidious onset and protracted incubation period. It is still unknown how silicosis develops. Furthermore, no current medications can stop the progression of silicosis and reverse pulmonary fibrosis.

The current mouse models for silicosis involve tracheal ingestion of a mixed suspension of CSD. For example, administering CSD into the lungs by adopting the cervical trachea trauma after anesthesia does not comply with repeated human exposure to dye dust7. The impact of exposure to ambient dust on individuals can be studied by exposing them to CSD in the form of aerosols, which more accurately reflects the environmental concentrations of this toxic substance8. However, environmental CSD cannot simply be inhaled directly into the lungs due to the unique physiological structure of the mouse nose9. Moreover, the equipment associated with this technology is expensive, which has caused researchers to re-evaluate the mouse silicosis model10. By inhaling CSD suspension through a nasal drip five times within 2 weeks, it was possible to build a dynamic model of silicosis. This model is consistent and safe while being easy to use. It is important to note that this study allows for repeated inhalation of CSD in mice. The mouse silicosis model created through this procedure is expected to be more beneficial for research requirements.

Access restricted. Please log in or start a trial to view this content.

Protocol

All procedures followed the guidelines of the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (NIH Publication No. 8023, revised 1978) and were approved by the Institutional Animal Care and Use Committee at the Medical School of Anhui University of Science and Technology.

1. Managing and feeding mice

  1. Assign 20 healthy C57BL/6 male mice to the experimental or vehicle groups in a 1:1 ratio. Acclimatize the mice to the new environment for 1 week.
  2. Provide a constant light time of 12 h per day. Use a time control switch for precise timing.

2. Preparing the CSD suspension

  1. At least 1 day before nasal drips, grind the silica in an agate mortar for 0.5 h.
  2. Observe the size and shape of the crystal particles. Take representative photographs using scanning electron microscopy (SEM).
    1. Use conductive tape to bind the particles to prepare the sample for SEM. Use a hair dryer to gently blow away the silicon particles that are not firmly bonded.
    2. Evacuate the sample chamber, turn on the high pressure, and capture the image.
      NOTE: The working distance (WD) between the lens and the sample is 5.9 mm, the accelerating voltage is 2.0 kV, and the magnification (Mag) is 100,000x, using the SignalA detector. The particles are dispersed with irregular crystallization, and approximately 80% have a diameter of 1-5 µm (Figure 1A).
  3. Make a 20 mg/mL sterile CSD suspension. Dilute the CSD using sterile saline and mix it with an ultrasonic shaker (40 kHz, 80 W) at room temperature (RT) for 30 min.
  4. Stir and mix the CSD suspension thoroughly on a vortex mixer for 10 s before administering the nasal drips.

3. Administering nasal drips to mouse

  1. Rapidly anesthetize a mouse with 2% isoflurane at a dose of 3.6 mL/h in an anesthesia machine (Figure 1B, left panel).
    NOTE: Anesthesia should be performed in a fume hood to avoid inhalation of the anesthetic by the technician. Ensure that the adequate depth of anesthesia by observing the change from rapid and irregular breathing to a slow and steady state in the mice.
  2. Drip 50 µL of the CSD nasally within 4-8 s (Figure 1B, right).
    1. For the nasal drip, place the head of the mouse on the researcher's metacarpophalangeal joint with the tip of the index finger.
    2. Keep the mouse in a prone position, with four fingers slightly flexed and the tip of the thumb lightly touching the lower lip of the mouse to straighten the airway. Avoid touching the pharynx to elicit the gag reflex.
    3. Aspirate 50 μl of liquid using a 200 μl pipette. Drop the liquid into the mouse's nasal cavity in three to four divided doses depending on the mouse's respiratory rate. Each instillation should consist of 15 to 20 μl liquid. Administer the drips once every 3 days, 5x within 12 days. Treat the control mouse with an equal amount of saline.
  3. Gently massage the heart area of the mouse 5x-10x for 5 s.
    1. Hold the mouse's body with the palm, pinch the skin on the back of the neck with the thumb and index finger, and fix the mouse's hind limbs with the other fingers. Then, gently press the mouse's heart-beating area with the index finger of the other hand 5-10 times in a period of 5 s.
  4. When the mouse's breathing has stabilized, place it in a recovery cage with a heating pad and observe until it recovers from anesthesia, then return the mouse to its home cage. Sacrifice the mouse at 31 days.

4. Collecting the lung tissues and preparing a paraffin section

  1. Inject 0.18 mL of 10% chloral hydrate intraperitoneally, ensuring that the mice do not respond to toe or tail stimulation (performed using the toothed forceps). Then, proceed to the next step.
  2. Fix the mouse limbs on a foam test board and spray with 75% alcohol to dampen the fur. Remove most of the thoracic ribs at the midline of the clavicle and open the thoracic cavity of the mice to expose the heart and lungs.
  3. Immediately cut open the right atrium with ophthalmic surgical scissors and slowly inject 20 mL of phosphate buffer (PBS) from the heart tip at the left atrial beat with the greatest amplitude to allow the whole blood to flow. Next, remove the lower lobe of the right lung and store it at -80 °C for western blotting analysis.
  4. Keep perfusing 10 mL of 4% paraformaldehyde (PFA) in the same site after the PBS injection. Collect the remaining lung and preserve the sample in 30 mL of 4% PFA for pathological analysis.
  5. After 72 h of fixation, embed specimens in paraffin.
    1. Dehydrate the tissues through a graded series of ethanol (EtOH) dilutions in deionized water (60%, 70%, 80%, 90%, 100%) for 1 h each at RT. Clear the sample in two washes of xylene for 1 h each.
    2. Infiltrate the samples with the melted paraffin wax by heating to 50 °C for 2 h. Repeat this process in another cylinder. Cool the wax molds with tissues for 1 h to harden.
    3. After the wax has hardened and the tissue has been embedded, use a paraffin sectioning machine to slice the tissue at 5 µm. The precise sectioning and slide mounting steps were previously described11.
      ​NOTE: Sufficient tissue perfusion is indicated by developing muscle twitching and tail twisting into an "S" shape or flexion after receiving 10 mL of 4% PFA.

5. Performing hematoxylin and eosin (HE) staining

  1. Heat the paraffin-embedded tissues on a hot plate (60 °C) for more than 4 h to allow for adhesion to the slides and improved deparaffination.
  2. Dewax and hydrate paraffin sections. Soak the slides with samples in xylene 2x for 30 min each time. Next, dip them in anhydrous ethanol, then 95%, 85%, 75% alcohol, and deionized water for 5 min, respectively.
  3. Perform hematoxylin and eosin staining. Stain the tissues in a hematoxylin staining bucket for 10 min. Rinse them with gently running water for 5 min. Then, dip the slides in the eosin staining bucket for 10 s.
  4. Dehydrate the samples in 75%, 85%, 95%, and anhydrous ethanol for 5 min each. Clear the tissue sections by immersing them in xylene for 5 min. Seal the section with approximately 60 µL of neutral resin drops. Place the cover slide over the section and carefully lower it to avoid air bubbles.

6. Performing Masson staining

  1. Dewax and hydrate the paraffin samples, as mentioned in step 5.2. Then, stain the cell nuclei with 50% Weigert's hematoxylin for 10 min. Soak the tissue in acidic ethanol liquefaction for 10 s and rinse the tissue slides gently with running water for nuclei bluing.
    NOTE: Prepare the Weigert's hematoxylin staining solution immediately before use.
  2. Stain the samples with drops of Lichun red staining solution (40 µL for each tissue slide) for 7 min and wash them with a weak acid working solution (30% hydrochloric acid) for 1 min to remove the unbound Lichun red dye.
  3. Dip them in 95% alcohol for 20 s and dehydrate them 2x with anhydrous ethanol for 1-3 s each. After that, clear the tissues with xylene and seal them with 60 µL of neutral resin drops, as mentioned in step 5.4.

7. Performing Sirius red staining

  1. Dewax and hydrate paraffin sections as mentioned in step 5.2.
  2. Infiltrate the sections for 1 h with Sirius red staining solution.
  3. Stain the cell nuclei of the samples for 8-10 min with Mayer hematoxylin staining solution. Rinse them gently with running water for 10 min. Then, dehydrate and clear the tissue slides. Seal them as mentioned in step 5.4.

8. Performing immunohistochemistry

  1. Dewax and hydrate the paraffin samples as described in step 5.2.
  2. Infiltrate the specimens with a 3 mg/mL EDTA antigen retrieval solution of about 30 mL. Boil for 20-30 min. Wash the tissues with deionized water, and then incubate them in phosphate-buffered solution containing 0.5% Tween-20 (PBST) for 5 min.
  3. Soak the samples for 15 min with 0.3% hydrogen peroxide solution to inactivate the endogenous peroxidase in the specimens. Wash them 3x with PBST for 5 min each time.
    NOTE: The 0.3% hydrogen peroxide solution must be made fresh in a light-proof environment.
  4. Permeabilize the membrane of specimens for 15 min with 0.3% Triton-100 solution. Then, block with 30-40 µL of 5% bovine serum albumin (BSA) for 1 h.
  5. Remove the blocking solution. Add diluted primary antibodies NF-κB (dilution 1:200) and CD68 (dilution 1:1,000) and incubate the specimens overnight at 2-8 °C in a microscope slide IHC wet box to prevent evaporation and light.
  6. The next day, transfer them to RT for 1 h. Then, wash them with PBST 3x for 5 min each.
  7. Incubate the samples for 1 h in rabbit anti-mouse horseradish peroxidase-labeled secondary antibodies (dilution ratio 1:500) at RT and wash them with PBST 3x for 5 min each.
    NOTE: Both primary and secondary antibodies were diluted with 5% BSA.
  8. Incubate samples with the 3,3'-Diaminobenzidine (DAB) substrate corresponding to the enzyme-labeled antibody for 5-20 min. Stop the reaction with deionized water when the optimal staining intensity is reached.
    NOTE: The DAB solution needs to be prepared freshly and protected from light. The color development reaction should be observed in real-time under the microscope to determine when to stop staining. Positive specimens exhibit intense staining, while negative specimens do not develop color.
  9. Counterstain the samples for 30 s with Weigert hematoxylin. Next, rinse the tissues under running water for 1 min. Then, dehydrate, clear, and seal the tissue slides, as mentioned in step 5.4.

9. Performing western blotting analysis

  1. Lyse the lung tissues to extract proteins. Add 200 µL of RIPA working solution to 20 mg of the lung tissue.
  2. Homogenize the tissue on ice for 5 min using a handheld electric grinder and incubate for 1 h on ice with gentle shaking. Afterward, centrifuge the homogenate at 4 °C for 15 min at 14,800 x g.
  3. Collect the supernatant and determine the protein concentration with the BCA protein assay kit. Make the protein storage solution with RIPA at 6 µg/µL protein. Add 20 µL of 5x loading buffer to the 80 µL of the protein lysate. Disrupt the secondary protein structure by heating the protein-containing microcentrifuge tubes in a metal bath (100 °C) for 20 min.
  4. After cooling, aliquot 100 µL of the protein storage solution into each tube and store the samples in a -80 °C refrigerator. Dilute the protein concentration to 2–3 μg/μL with 1x loading buffer before electrophoresis.
    NOTE: The protein extraction process should be performed on ice. For the RIPA working solution, add 1 µL of 100 mM phenylmethylsulfonyl fluoride (PMSF) to 99 µL of RIPA to inhibit phosphorylated protein degradation.  Prepare 1x loading buffer by diluting 5x loading buffer with RIPA at a ratio of 1:4. 
  5. Add 20 µg of samples to each well and run the gel. For 5% concentrated gels, use 80 V for 20 min to have the proteins electrophoresed down from the same starting point. For 10% isolated gels, run at 100 V for 1 h to allow the proteins of different molecular weights to be separated as much as possible.
  6. Pre-activate the PVDF membrane with methanol for 20 s. Transfer the proteins to the PVDF membrane using the wet transfer method with 400 mA current for 1-2 h.
    NOTE: Ensure that the electrophoresis tank and the electrotransfer tank are horizontal. Cool the entire tank with ice, as the membrane transfer process generates much heat.
  7. Wash the membrane with TBST solution for 5 min each time, 5x. Then, block with 5% BSA or 5% skim milk for 1 h. Dilute the primary antibodies NF-κB (1:1,000) and β-actin (1:1,000) with 5% BSA. Submerge the strips in the antibody solution and shake the strips gently overnight at 2-8 °C.
  8. Wash the strips with PBST. Next, dilute horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (1:10,000) and incubate them in the diluted secondary antibody for 1 h at RT with gentle shaking.
  9. Prepare an enhanced chemiluminescence (ECL) developer, drop it on the strip, and incubate for 3 min.
  10. Expose the strip to a gel imager for 20 s. Measure the gray value of the strip to assess the protein level by system software. Use β-actin as an internal control.

Access restricted. Please log in or start a trial to view this content.

Results

The potential pathogenesis of silicosis in mice was investigated using the proposed method. We found that the body weight of the mice in the experimental group decreased significantly relative to the control group and that the body weight recovered slowly after cessation of exposure. Due to the optimized dose used here, no mortality was observed in silica-exposed mice in this experiment. The technical roadmap of repeated nasal drip to CSD is shown in (Figure 1). The previously described proc...

Access restricted. Please log in or start a trial to view this content.

Discussion

Silicosis mouse models are crucial for studying the pathogenesis and treatment of silicosis. This protocol describes a method for preparing a model of silicosis in mice through repeated nasal exposure. This method allows for the study of the pathological characteristics of silicosis induced by different exposure times. Mice were anesthetized on a ventilator, and their respiratory rate was monitored. The initial short, fast breathing rate gradually slowed and deepened over time. The anesthesia caused the mice's muscles to...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare no conflicts of interest.

Acknowledgements

This study was supported by the University Synergy Innovation Program of Anhui Province (GXXT-2021-077) and the Anhui University of Science and Technology Graduate Innovation Fund (2021CX2120).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.5 mL tubeBiosharpBS-05-M
10% formalin neutral fixativeNanchang Yulu Experimental Equipment Co.NA
Adobe IllustratorAdobe NA
Alcohol disinfectantXintai Kanyuan Disinfection Products Co.NA
CD68Abcamab125212
Citrate antigen retrieval solutionbiosharp life scienceBL619A
DAB chromogenic kitNJJCBioW026-1-1
Dimethyl benzeneWest Asia Chemical Technology (Shandong) CoNA
Enhanced BCA protein assay kitBeyotime BiotechnologyP0009
Hematoxylin and Eosin (H&E)Beyotime BiotechnologyC0105S
HRP substrateMillipore CorporationP90720
HRP-conjugated Affinipure Goat Anti-Rabbit IgG(H+L)ProteintechSa00001-2
Iceacetic acidWest Asia Chemical Technology (Shandong) CoNA
ImageJNIHNA
IsofluraneRWD Life ScienceR510-22
Masson's Trichrome stain kitSolarbioG1340
MethanolMacklinNA
MicrotubesMilliporeAXYMCT150CS
NF-κB p65Cell Signaling Technology8242S
Oscillatory thermostatic metal bathAbsonNA
Paraffin embedding machinePrecision (Changzhou) Medical Equipment Co.PBM-A
Paraffin SlicerJinhua Kratai Instruments Co.NA
Phosphate buffer (PBS) BiosharpBL601A
Physiological saline The First People's Hospital of Huainan CityNA
PipettesEppendorfNA
PMSFBeyotime BiotechnologicalST505
Polarized light microscopeOlympusBX51
Precision balanceAcculabALC-110.4
Prism7.0GraphPad Version 7.0
PVDF membranesMillipore3010040001
RIPA lysis bufferBeyotime BiotechnologyP0013B
RODI IOT intelligent multifunctional water purification systemRSJRODI-220BN
Scilogex SK-D1807-E 3D ShakerScilogexNA
SDS-PAGE gel preparation kitBeyotime BiotechnologyP0012A
Silicon dioxidSigma#BCBV6865
Sirius red stainingNanjing SenBeiJia Biological Technology Co., Ltd.181012
Small animal anesthesia machineAnhui Yaokun Biotech Co., Ltd.ZL-04A
Universal Pipette Tips (0.1–10 µL)KIRGENKG1011
Universal Pipette Tips (100–1000 µL)KIRGENKG1313
Universal Pipette Tips (1–200 µL)KIRGENKG1212
Vortex mixer VWRNA
ZEISS GeminiSEM 500Zeiss GermanySEM 500
β-actinBiossbs-0061R

References

  1. Olsson, A., Kromhout, H. Occupational cancer burden: the contribution of exposure to process-generated substances at the workplace. Molecular Oncology. 15 (3), 753-763 (2021).
  2. The Lancet Respiratory. The world is failing on silicosis. The Lancet. Respiratory Medicine. 7 (4), 283(2019).
  3. Weissman, D. N. Progressive massive fibrosis: An overview of the recent literature. Pharmacology & Therapeutics. 240, 108232(2022).
  4. Lancet, C. C., Yu, I. T., Chen, W. Silicosis. Lancet. 379 (9830), 2008-2018 (2012).
  5. Mazurek, J. M., Wood, J., Blackley, D. J., Weissman, D. N. Coal workers' pneumoconiosis-attributable years of potential life lost to life expectancy and potential life lost before age 65 years - United States, 1999-2016. MMWR. Morbidity and Mortality Weekly Report. 67 (30), 819-824 (2018).
  6. Voelker, R. Black Lung resurgence raises new challenges for coal country physicians. JAMA. 321 (1), 17-19 (2019).
  7. Nakashima, K., et al. Regulatory role of heme oxygenase-1 in silica-induced lung injury. Respiratory Research. 19 (1), 144(2018).
  8. Li, Y., et al. Minute cellular nodules as early lesions in rats with silica exposure via inhalation. Veterinary Sciences. 9 (6), 251(2022).
  9. Salehi, F., et al. Immunological responses in C3H/HeJ mice following nose-only inhalation exposure to different sizes of beryllium metal particles. Journal of Applied Toxicology. 29 (1), 61-68 (2009).
  10. Yang, T., et al. Emodin suppresses silica-induced lung fibrosis by promoting Sirt1 signaling via direct contact. Molecular Medicine Reports. 14 (5), 4643-4649 (2016).
  11. Cornell, W. C., et al. Paraffin embedding and thin sectioning of microbial colony biofilms for microscopic analysis. Journal of Visualized Experiments. (133), e57196(2018).
  12. Li, B., et al. A suitable silicosis mouse model was constructed by repeated inhalation of silica dust via nose. Toxicology Letters. 353, 1-12 (2021).
  13. Mu, M., et al. Coal dust exposure triggers heterogeneity of transcriptional profiles in mouse pneumoconiosis and Vitamin D remedies. Particle and Fibre Toxicology. 19 (1), 7(2022).
  14. Kato, K., et al. Muc1 deficiency exacerbates pulmonary fibrosis in a mouse model of silicosis. Biochemical and Biophysical Research Communications. 493 (3), 1230-1235 (2017).
  15. Liu, F., et al. CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice. PLoS One. 5 (11), 15404(2010).
  16. Mansouri, N., et al. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes. JCI Insight. 4 (21), 128060(2019).
  17. Ohtsuka, Y., Wang, X. T., Saito, J., Ishida, T., Munakata, M. Genetic linkage analysis of pulmonary fibrotic response to silica in mice. The European Respiratory Journal. 28 (5), 1013-1019 (2006).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Pulmonary FibrosisNasal Drip AdministrationLung HistologyMasson StainingImmunohistochemistry StainingWestern BlotMacrophage Activation

Related Articles